🇺🇸 FDA
Pipeline program

Dexlansoprazole MR

T-GI04-088

Phase 3 small_molecule completed

Quick answer

Dexlansoprazole MR for Gastroesophageal Reflux Disease is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 4 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Gastroesophageal Reflux Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials